mRNA Analytical Development Summit on February 13-15, 2024 in Boston, United States

Welcome to the 3rd mRNA Analytical Development Summit US

Empowering Advanced Analytics for Exceptional mRNA Therapeutics and Vaccines

As access to faster and higher-throughput analytical methods becomes increasingly vital, it is critical that we employ superior analytical approaches within mRNA-based therapeutics and vaccines to safeguard the identity, safety, and efficacy of these promising medicines.

Following an exciting and highly valued iteration of discussions and presentations in 2023, the 3rd mRNA Analytical Development Summit returns to Boston once more as the only industry dedicated forum to exhibit latest advances in novel analytical techniques to guarantee the extensive characterization of mRNA and nanoparticle quality attributes.

This must-attend event is designed for Analytical Development, Quality Control, CMC, and Regulatory experts seeking to stay at the forefront of mRNA therapeutics and vaccines. Join 180+ experts from across the globe and gain a better understanding of future analytical methods to safeguard your regulatory submissions in 2024 and beyond. Avoid missing out on networking with those shaping the landscape of novel and emerging analytical tools and technologies for mRNA-based therapeutics and vaccines. Meet your community face-to-face in 2024 to hear how they address the major challenges facing the industry.

URLs:

Tickets: https://go.evvnt.com/2055971-2?pid=10008

Brochure: https://go.evvnt.com/2055971-3?pid=10008

Time: 8:00 am - 5:00 pm

Prices:

Drug Developer - Conference + 3 Workshops: USD 4896.00,

Drug Developer - Conference Only: USD 2999.00,

Academic - Conference + 3 Workshops: USD 4196.00,

Academic - Conference Only: USD 2599.00,

Solution Provider - Conference + 3 Workshops: USD 5896.00,

Solution Provider - Conference Only: USD 3699.00

Speakers: Andrew Geall, Chief Development Officer, Replicate Bioscience, Benjamin Hall, Senior Scientist, Tessera Therapeutics, Bo Ma, Senior Advisor, Eli Lilly and Co., Corey Perez, Principal Scientist - Discovery, Senda Biosciences, Curtis Dobrowolski, Co-Founder, Nava Therapeutics, Deanna Di Grandi, Research Associate, Regeneron Pharmaceuticals Inc, Gilles Besin, Chief Scientific Officer, Orbital Therapeutics, Heinrich Haas, Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, Husain Attarwala, Vice President, Drug Metabolism, Pharmacokinetics, Clinical Pharmacology and Analytical Sciences, aera, Jean-Noel, Lemercier AD, Editas Medicine, Jianmei Kochling, US Head of Analytical Sciences, Sanofi, John Haserick, Vice President of Platform Development, Innovac Therapeutics, Julia Baek. Senior Scientist II, ReCode Therapeutics, Inc, Maciej Wieczorek, Chief Executive Officer, Celon Pharma, Paolo Martini, CSO International Therapeutics Research Centers, Founder of Moderna Rare Diseases, Moderna, Quinner Baltazar, Associate Director, SalioGen Therapeutics, Ravikiran Yerabolu, Associate Principal Scientist, Merck and Co, Siddarth Bhoraskar, Scientist II, Analytical Research and Development, Beam Therapeutics, Sonia Golombek, Senior R and D Manager, Elastrin Therapeutics, Tiffany Brucker, Sr. Manager Analytical Development, GlaxoSmithKline Plc, Yimin Hua, Head of Biochemistry Analytical Development, Sanofi, Zack Zhang, Director, Analytical Development, Beam Therapeutics